Introduction

Alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV; OMIM no. 265380) is a rare lung disorder that presents in the early neonatal period. It affects both parenchymal and pulmonary vasculature development.1, 2 The characteristic histologic features include malpositioned (misaligned) pulmonary veins that run alongside small pulmonary arteries both in their pre-acinar and intra-acinar course and, at times with the arteries within a common adventitial sheath, rather than in their normal location within interlobular septa or at the lobular periphery;3, 4 increased smooth muscles in small pulmonary arteries; lobular underdevelopment and a severe deficiency of normally positioned and normal sized capillaries in alveolar walls.3, 5 A third of the cases also have lymphangiectasis.3 Most cases of ACD/MPV are sporadic with only a few reported familial cases (10%).4, 6, 7, 8, 9 Affected infants typically present with pulmonary hypertension within a few hours of birth and despite treatment with positive pressure oxygen, nitric oxide, sildenafil and/or extracorporeal membrane oxygenation, clinical improvement is limited and survival is brief.10, 11, 12 A few cases of late presentation and longer survival have been reported.10, 13, 14 The disorder has more often been diagnosed histopathologically at autopsy of affected infants; however, increasing reports of biopsy diagnosis are being made. A very high percentage (80%) of ACD/MPV patients has a variety of associated anomalies particularly of the gastrointestinal, cardiovascular and genitourinary systems.3

We have been involved in research related to ACD/MPV since 2000 and have accumulated a large collection (>80) of tissue and DNA samples from patients with ACD/MPV and their immediate family members. The parents’ organization ‘ACD Association (ACDA)’ has been of great help in recruiting new patients and spreading the information about our research (http://www.acd-association.com). ‘The Breath of Life Project’ (http://www.breathoflifeproject.com) has recently begun educating health professionals about ACD/MPV as a part of a Centers for Disease Control and Prevention (CDC)-funded awareness project.

In 2009, we showed that a segment of ACD/MPV patients in our cohort had either inactivating point mutations in the FOXF1 gene or deletions at 16q24.1, which were both genic and upstream to FOXF1.15

Materials and methods

The affected infants, their parents, healthy sibling and grandparents were enrolled in our ongoing study of the genetic basis of ACD/MPV, approved by the Baylor Institutional Review Board (H-8712) after their signed consent. Lung histology was reviewed by CL to confirm ACD/MPV (Figure 1).

Figure 1
figure 1

Histopathological findings in term female (a, 39 weeks gestation; 17 days life span) (Table 1: Patient 1) and 21-weeks-old male fetus (b) (Table 1: Patient 2). The lungs show characteristic histological findings of ACD/MPV with pulmonary vein misalignment, arterial medial thickening and lobular underdevelopment even in the lung of the immature male fetus (b). For both, white arrows indicate misaligned pulmonary veins and black arrows identify small pulmonary arteries with smooth muscle hyperplasia. Nearby bronchioles are identified as B. The lobular parenchyma for the term infant shows enlarged and poorly subdivided air spaces, diminished numbers of normally positioned capillaries and marked venous congestion. For the fetus (b), the lobular parenchyma appears immature for the gestational age with simple rounded air spaces without evidence of early secondary crest formation, and with persistent subnuclear glycogen evident in the uniform cuboidal epithelium.

The pedigree of this Caucasian family of Central European origin is shown in Figure 2. Among six children in the family only one is healthy (Figure 2; II 05). Three infants (Figure 2; II 01, II 03 and II 04) died in the neonatal period and two fetuses (Figure 2; II 02 and II 06) were terminated at 21 and 22 weeks of gestation, respectively, for severe urinary tract anomalies (Table 1). The parents are non-consanguineous.

Figure 2
figure 2

Pedigree of the described family. Five of the six children were affected with ACD/MPV. The arrow shows the proband. DNA from II 02, II 04 and II 06 identified the c.416G>T;p.Arg139Leu mutation. Smaller squares indicate terminations of pregnancies. The proband is shown with an arrow.

Table 1 Clinical information about the ACD/MPV infants in the family reported

DNA from patient tissue samples were isolated using Qiagen’s (Germantown, MD, USA) DNeasy Blood and Tissue kit using manufacturer’s instructions. DNA from blood of the parents, healthy sibling and grandparents were isolated using Gentra Puregene isolation kit following the manufacturer’s instruction. The PCR primers (The primers were synthesized in the Laboratory of Dr Partha Sen, Baylor College of Medicine, TX, USA, using ABI 3900 DNA Synthesizer, Foster City, CA, USA.) and cycling protocol are shown below.

Cycling conditions: 94 °C 3 min, 40 cycles of 94 °C for 30 sec, 54 °C for 30 sec, 72 °C for 1 min; final extension at 72 °C for 5 min.

Genotyping of 733,202 SNPs was done using Illumina (San Diego, CA, USA) OmniExpress beadarrays, following manufacturer’s instructions, to investigate the haplotype encompassing FOXF1 on chromosome 16.

Results

Diagnosis of familial ACD/MPV was based on the identification of characteristic histopathological changes in the lungs in three of the five affected subjects (Figure 2; II 01, II 02, II 06) present even in the more immature fetal lungs. All showed lobular underdevelopment, capillary deficiency and misalignment of pulmonary veins (Figure 1). The clinical details of the patients are shown in Table 1. A missense heterozygous mutation of G>T at the 416 position that changes an arginine to leucine at position 139 of the predicted protein sequence (c416G>T; p.Arg139Leu) was identified within the DNA-binding domain of FOXF116, 17 (Figure 3). The mutation was identified in DNA samples from three affected infants (Figure 2; II 02, II 04 and II 06, and 2, 4, 5 Table 1). No DNA samples were available from the two other affected infants (Figure 2; II 01; II 03, and 1, 3 Table 1). The same mutation was also identified in the DNA sample from the mother (Figure 3) who had heart scratch in her childhood without any recognized heart defect or cardiac function that faded away later in her life. She also had a tracheal stenosis at 3 years of age, which was resolved by dilatation. She is without any respiratory problems now. The unaffected child (Figure 2; II 05) and the father of the children do not have the mutation (Figure 3) and are clinically well. The mutation in the mother arose de novo as it was not found in her parents or siblings. This mutation is not one of the SNPs reported in the dbSNP and is not cited in the Exome Variant Server, NHLBI Exome Sequencing Project (ESP; Seattle, WA, USA) (http://evs.gs.washington.edu/EVS/), which covers more than 10 000 alleles. The mutation was predicted to be deleterious by two programs viz. PolyPhen-2 and Aligned GVGD.18, 19

Figure 3
figure 3

DNA sequencing showing the heterozygous mutation (c416G>T). (a) DNA from the father; (b) DNA from the mother; (c) DNA from one of the affected children (Figure 2; II 06); (d) DNA from the unaffected child (Figure 2. II 05). The arrows indicate the mutated base. A and D are homozygous for the wild-type allele, whereas B and C show double peak for G and T indicating a heterozygous mutation.

Haplotype analysis was carried out using Illumina OmniExpress arrays that genotype 733,202 SNPs. Using an interval of approximately 1 Mb flanking the FOXF1 locus, we selected 214 SNPs with low inter-marker linkage disequilibrium (r2<0.2) using the HapMap CEU population as the reference. We then removed markers that were monomorphic among the three unrelated individuals in the pedigree (maternal grandfather, maternal grandmother and father), leaving 145 markers for haplotype analysis. Haplotypes were inferred using the EM algorithm and logic rules implemented in HAPLORE software (http://bioinformatics.med.yale.edu/group/software.html). The results show that the affected children inherited the same haplotype from their mother. The unaffected sibling inherited the alternate maternal haplotype. By reference to the genotypes of the maternal grandparents, the haplotype bearing the FOXF1 mutation was inherited from their maternal grandfather (Figure 4).

Figure 4
figure 4

(a) Result of the haplotype analysis using Illumina Omni express platform. The analysis is centered on FOXF1 (Chr16:85,000,000–85,200,000, hg18). The colored boxes identify chromosomes in different individuals. The affected children in generation III have the same maternal chromosome from their mother that she inherited from her father. The unaffected child has the other chromosome from their mother which she inherited from her mother. (b) A detail of the informative SNPs. F: father; M: mother, AF1 and AF2: affected child 1 and 2, UN: unaffected child, MGF and MGM: maternal grandfather and grandmother, respectively. The SNP numbers are shown on the right. Identity of the inherited chromosomes are indicated by * and †.

Discussion

FOXF1 is a transcription factor expressed in the lung mesenchyme during development.16 It is essential for cell migration during embryonic and fetal development.20 Our previous work has shown that abnormalities of FOXF1 are associated with ACD/MPV.15 The mouse Foxf1 and the human FOXF1 proteins act in a haploinsufficient manner.15, 21, 22, 23 FOXF1 has been predicted bioinformatically to be paternally imprinted in the humans;24 however, a paternal uniparental disomy of chromosome 16 (UPD16pat) resulted in an otherwise normal child with only some fetal and postnatal growth retardation.25 Interestingly, all the genic and upstream deletions in our cohort of patients reported previously15 occurred on the maternal chromosome 16, which suggested that FOXF1 might be paternally imprinted. We have since identified eight additional deletions upstream of FOXF1 and two deletions involving FOXF1 in ACD/MPV patients. Seven of these deletions, for which parental origin could be determined, arose de novo on the maternal chromosome (P Szafranski, personal communication).

In this article, we present a unique familial case of ACD/MPV with five affected subjects among who were two female and one male infants that died of ACD/MPV; additionally, the mother had two pregnancy terminations because of severe obstructive uropathy (Table 1; Figure 2). The family has one unaffected child. Pathological examination of the lungs of the affected infants and the fetal terminations show typical features of ACD/MPV (Figure 1). The mutation in the infants is inherited from their healthy mother who is heterozygous for the identical mutation (Figure 3). The history of tracheal stenosis in the mother fits well with the mild end of the spectrum of FOXF1 deficiency26 and can be explained by a higher local dosage sensitiveness of the FOXF1 protein required for trachea development when compared with the lungs. The absence of the mutation in DNA sequenced from the maternal grandparents and uncle and aunt of the children confirmed that the mutation in the mother is de novo. The change of an arginine to leucine most likely affects the function of the protein as arginine is a basic amino acid and leucine a nonpolar one.27 Further, the arginine at this position is highly conserved in the FOX genes.17

It is evident that the affected children died of ACD/MPV due to the mutation in the FOXF1 gene. They inherited the mutation from their mother and therefore, the mutation is present on their maternal chromosome 16. The healthy child inherited the wild-type copy of chromosome 16 from the mother. Further, the mother has the mutation and has no features of ACD/MPV, suggesting that the mutation in her is present on the paternal chromosome 16. This clearly supports the possibility that FOXF1 is paternally imprinted with only the maternal copy being expressed. We reported a paternally inherited no-stop mutation in the second exon (last codon) in FOXF1 in a patient with ACD/MPV.15 We believe that the aberrant and extended transcript might have escaped nonsense-mediated decay and negatively acted on the maternal wild-type copy of the transcript, resulting in ACD/MPV.

The imprinted nature of FOXF1 has been predicted previously.24, 25 To confirm the lineage of the inheritance of the maternal chromosome in the affected infants and the unaffected child, we performed a haplotype analysis using Illumina OmniExpress. The result (Figure 4) implies a model in which the mother, who carries a de novo mutation in FOXF1, is healthy because the mutation is on her paternal chromosome; however, the same mutation when transmitted to her offspring results in ACD/MPV. The data strongly suggest that FOXF1 is predominantly expressed from the maternal copy. Further evidence that deletions in the 16q24.1 region in ACD/MPV patients are all on the maternal chromosome strongly supports this model. Szafranski et al (P Szafranski, personal communication) have shown that the 75-kb regulatory region mapping at 250 kb upstream of FOXF1 is differentially methylated, which indicates that the gene may be differentially expressed. This result along with the UPD16pat data suggests that the expression of FOXF1 might be complex and imprinting of this gene can be incomplete with the maternal copy being predominantly expressed. It is possible that the expression of the gene from two paternal copies might be just adequate to fulfill its functional requirements as evidenced by a normal child with UPD16pat.

Thus, our data further confirm that FOXF1 is implicated in ACD/MPV and that the gene is maternally expressed and paternally imprinted in human. We plan to investigate the role of methylation in regulating the expression of this gene. Tissue-specific methylation has been shown to regulate Foxf1 expression in mice28 and methylation patterns have been conserved in eukaryotic evolution.29, 30 It will be interesting to investigate tissue-specific pattern of methylation of FOXF1 in humans as a majority of the ACD/MPV patients also have anomalies of other organ systems.3, 4 Eventually, we would like to understand the molecular role of FOXF1 in lung development, thereby providing counseling and possibly treatment for patients with ACD/MPV and their families in future.